Subjects -> MEDICAL SCIENCES (Total: 8529 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (332 journals)
    - DENTISTRY (292 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (41 journals)
    - HEMATOLOGY (155 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (167 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2342 journals)
    - NURSES AND NURSING (362 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (381 journals)
    - OTORHINOLARYNGOLOGY (82 journals)
    - PATHOLOGY (98 journals)
    - PEDIATRICS (273 journals)
    - PSYCHIATRY AND NEUROLOGY (822 journals)
    - RESPIRATORY DISEASES (103 journals)
    - RHEUMATOLOGY (78 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (401 journals)

RESPIRATORY DISEASES (103 journals)                     

Showing 1 - 104 of 104 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
Advances in Thoracic Diseases     Open Access   (Followers: 1)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 257)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 17)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archives of Pulmonology and Respiratory Care     Open Access   (Followers: 2)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 2)
BMC Pulmonary Medicine     Open Access   (Followers: 5)
BMJ Open Respiratory Research     Open Access   (Followers: 7)
Breathe     Open Access   (Followers: 5)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal   (Followers: 1)
Canadian Respiratory Journal     Open Access   (Followers: 3)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 102)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 6)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 16)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 2)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 3)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 4)
European Respiratory Journal     Full-text available via subscription   (Followers: 39)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal   (Followers: 1)
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 14)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 5)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 5)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 5)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 5)
Journal of Respiratory Research     Open Access   (Followers: 2)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 3)
Lung Cancer     Hybrid Journal   (Followers: 16)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 2)
Open Respiratory Medicine Journal     Open Access   (Followers: 2)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 3)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 2)
Pulmonology and Respiratory Research     Open Access   (Followers: 2)
Respiratory Care     Full-text available via subscription   (Followers: 11)
Respiratory Investigation     Full-text available via subscription   (Followers: 1)
Respiratory Medicine     Hybrid Journal   (Followers: 18)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 35)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 38)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  


Similar Journals
Journal Cover
The Lancet Respiratory Medicine
Journal Prestige (SJR): 7.746
Citation Impact (citeScore): 5
Number of Followers: 35  
  Full-text available via subscription Subscription journal
ISSN (Print) 2213-2600 - ISSN (Online) 2213-2600
Published by Elsevier Homepage  [3203 journals]
  • [Correspondence] Cystic fibrosis in Turkey
    • Authors: Deniz Dogru; Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Sevgi Pekcan, Uğur Özçelik, board members the working group of the Cystic Fibrosis Registry of Turkey
      Abstract: We read with great interest The Lancet Respiratory Medicine Commission by Scott Bell, Felix Ratjen, and colleagues,1 which gives a comprehensive global perspective on cystic fibrosis care. We were pleased to see that the Commission gave a special focus to cystic fibrosis care in Turkey. However, in the space available, the authors were able to provide only brief details of clinical care in the country and we would like to take the opportunity to provide further information.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-04
      DOI: 10.1016/S2213-2600(20)30055-2
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Time to rename COPD exacerbations: implementing the term
           lung attack
    • Authors: Sebastiaan Holverda; Michael R Rutgers, Huib A M Kerstjens
      Abstract: Mona Bafadhel and colleagues make a compelling case for replacing the term exacerbation in chronic obstructive pulmonary disease (COPD).1 The most important reason for the proposed change is that less than 2% of patients with COPD know what the term exacerbation means, and hence do not realise the urgency of the event. Many physicians, too, do not have a sense of urgency around the term and, for instance, are unaware that 2-year mortality after a hospitalisation for COPD exacerbation is higher than that for a heart attack.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-04
      DOI: 10.1016/S2213-2600(20)30123-5
      Issue No: Vol. 8, No. 4 (2020)
  • [Corrections] Correction to Lancet Respir Med 2020; 8: e20
    • Abstract: Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 2020; 8: e20—In this Correspondence, the author's affiliation has been corrected and the following sentence has been corrected: “A trend towards an association was seen between smoking and severity of COVID-19 in the study by Guan and colleagues4 (11·8% of patients with non-severe disease were smokers vs 16·9% who had severe disease)…”. These corrections have been made to the online version as of April 1, 2020, and the printed version is correct.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-04
      DOI: 10.1016/S2213-2600(20)30130-2
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] COVID-19: the need for continuous medical education and
    • Authors: Li Li; Qianghong Xv, Jing Yan
      Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) moved rapidly through China, and the virus had spread to more than 60 countries and infected nearly 90 000 patients by March 5, 2020. Based on data for 72 314 cases of coronavirus disease 2019 (COVID-19), 14% of people have severe disease, 5% have critical illness, and 2·3% die.1 COVID-19 is not a conventional disease, and rapid changes in the provision of critical care have been needed to meet the needs of patients. Health emergencies such as the COVID-19 outbreak can be a huge challenge for critical-care physicians, who need strong comprehensive skills to respond effectively.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-16T23:30:06Z
      DOI: 10.1016/S2213-2600(20)30125-9
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] COVID-19, ECMO, and lymphopenia: a word of caution
    • Authors: Brandon Michael Henry
      Abstract: Extracorporeal membrane oxygenation (ECMO) can serve as life-saving rescue therapy for refractory respiratory failure in the setting of acute respiratory distress syndrome, such as that induced by coronavirus disease 2019 (COVID-19). In the study by Yang and colleagues,1 who compared clinical characteristics and outcomes in patients with severe COVID-19, five (83%) of six patients receiving ECMO died. Although this sample was small, and specific baseline characteristics and disease courses were almost unknown, it raises concerns about potential harms of ECMO therapy for COVID-19.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-13T23:30:03Z
      DOI: 10.1016/S2213-2600(20)30119-3
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Sex difference and smoking predisposition in patients
           with COVID-19
    • Authors: Hua Cai
      Abstract: The outbreak of novel coronavirus disease 2019 (COVID-19) is quickly turning into a pandemic. Although the disease is now better contained in China, 32 702 cases remain as of March 2, 2020. 10 566 cases and 166 deaths outside of China had been reported as of March 3 (WHO situation report 43), which is a large increase from the 2918 cases and 44 deaths reported on Feb 26 (WHO situation report 37). Rapid progress has been made with diagnostic reagents (eg, nucleic acid detection and detection of IgM or IgG, or both), drug repurposing (eg, remdesivir and chloroquine), and vaccine production.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-11T23:30:14Z
      DOI: 10.1016/S2213-2600(20)30117-X
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Are patients with hypertension and diabetes mellitus at
           increased risk for COVID-19 infection'
    • Authors: Lei Fang; George Karakiulakis, Michael Roth
      Abstract: The most distinctive comorbidities of 32 non-survivors from a group of 52 intensive care unit patients with novel coronavirus disease 2019 (COVID-19) in the study by Xiaobo Yang and colleagues1 were cerebrovascular diseases (22%) and diabetes (22%). Another study2 included 1099 patients with confirmed COVID-19, of whom 173 had severe disease with comorbidities of hypertension (23·7%), diabetes mellitus (16·2%), coronary heart diseases (5·8%), and cerebrovascular disease (2·3%). In a third study,3 of 140 patients who were admitted to hospital with COVID-19, 30% had hypertension and 12% had diabetes.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-11T23:30:13Z
      DOI: 10.1016/S2213-2600(20)30116-8
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Adoption of COVID-19 triage strategies for low-income
    • Authors: Rodgers R Ayebare; Robert Flick, Solome Okware, Bongomin Bodo, Mohammed Lamorde
      Abstract: Despite major advances in epidemic preparedness, Africa remains uniquely susceptible to novel coronavirus disease 2019 (COVID-19). According to the Infectious Disease Vulnerability Index,1 22 of the 25 countries most susceptible to an infectious disease outbreak are in Africa. The high prevalence of HIV, tuberculosis, and other pathogens might potentiate the severity of COVID-19 and contribute to diagnostic uncertainty. Health-care systems and human resources are already spread thin. And although the young age of the population (with more than half aged younger than 20 years) might prove protective, it also means that Africa has much to lose in terms of disability-adjusted life years.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-11T23:30:05Z
      DOI: 10.1016/S2213-2600(20)30114-4
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Respiratory support for patients with COVID-19 infection
    • Authors: Silvio A Ñamendys-Silva
      Abstract: As of Feb 27, 2020, coronavirus disease 2019 (COVID-19) has affected 47 countries and territories around the world.1 Xiaobo Yang and colleagues2 described 52 of 710 patients with confirmed COVID-19 admitted to an intensive care unit (ICU) in Wuhan, China. 29 (56%) of 52 patients were given non-invasive ventilation at ICU admission, of whom 22 (76%) required further orotracheal intubation and invasive mechanical ventilation. The ICU mortality rate among those who required non-invasive ventilation was 23 (79%) of 29 and among those who required invasive mechanical ventilation was 19 (86%) of 22.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-05T23:30:04Z
      DOI: 10.1016/S2213-2600(20)30110-7
      Issue No: Vol. 8, No. 4 (2020)
  • [Corrections] Correction to Lancet Respir Med 2020; published online Feb
    • Abstract: Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med 2020; published online Feb 21.—In this Article, Tables 1, 2, and 3 have been updated. These corrections have been made to the online version as of Feb 28, 2020, and will be made to the printed version.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-28T23:30:04Z
      DOI: 10.1016/S2213-2600(20)30103-X
      Issue No: Vol. 8, No. 4 (2020)
  • [Corrections] Correction to Lancet Respir Med 2020; 8: 420–22
    • Abstract: Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420–22—In this Case Report “by obtaining biopsy samples at autopsy” has been replaced with “by postmortem biopsies” in paragraph 1, “microvascular” has been replaced with “microvesicular” in two incidences in paragraph 5, and “(B) Frequency of Th17 (CD4+ CCR6+CCR4+) subset” has been changed to “(B) Frequency of Th17 (CD4+ CCR6+) subset” on page 3 of the appendix.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-25T23:30:07Z
      DOI: 10.1016/S2213-2600(20)30085-0
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Staff safety during emergency airway management for
           COVID-19 in Hong Kong
    • Authors: Jonathan Chun-Hei Cheung; Lap Tin Ho, Justin Vincent Cheng, Esther Yin Kwan Cham, Koon Ngai Lam
      Abstract: Medical professionals caring for patients with coronavirus disease 2019 (COVID-19) are at high risk of contracting the infection.1 Aerosol-generating procedures, such as non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), bag-mask ventilation, and intubation are of particularly high risk.2 We hereby describe the approach of our local intensive care unit (North District Hospital, Sheung Shui, Hong Kong) to managing the risks to health-care staff, while maintaining optimal and high-quality care.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-24T23:30:05Z
      DOI: 10.1016/S2213-2600(20)30084-9
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Obstructive sleep apnoea in acute coronary syndrome
    • Authors: Yüksel Peker
      Abstract: Whether patients with coronary artery disease should be screened for obstructive sleep apnoea, and consequently treated with continuous positive airway pressure (CPAP), regardless of excessive daytime sleepiness, is a hot topic. Previous randomised controlled trials on the effect of CPAP on cardiovascular outcomes in patients with sleep apnoea—namely, the RICCADSA1 and SAVE2 trials—reported neutral findings in intention-to-treat analyses. Thus, it is not surprising that current results from the ISAACC trial (examining the effect of obstructive sleep apnoea and CPAP on cardiovascular events in patients with acute coronary syndrome), reported by Manuel Sánchez-de-la-Torre and colleagues,3 are similarly neutral, given that the overall CPAP adherence was too low (mean 2·8 h per night) to expect an effect.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-05T23:32:39Z
      DOI: 10.1016/S2213-2600(20)30042-4
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Obstructive sleep apnoea in acute coronary syndrome
    • Authors: Miguel A Martinez-Garcia; Francisco Campos-Rodriguez, David Gozal
      Abstract: We carefully read the results of the ISAACC study1 and the excellent accompanying Comment.2 In the Article, and to a greater extent in the Comment, the limitations of the ISAACC study are well articulated and highlighted. However, some key additional points need attention.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-05T23:31:19Z
      DOI: 10.1016/S2213-2600(20)30040-0
      Issue No: Vol. 8, No. 4 (2020)
  • [Correspondence] Obstructive sleep apnoea in acute coronary syndrome
           – Authors' reply
    • Authors: Manuel Sánchez-de-la-Torre; Alicia Sánchez-de-la-Torre, Ferran Barbé
      Abstract: We thank Miguel Martinez-Garcia and colleagues as well as Yüksel Peker for sharing their interesting Correspondence about the ISAACC1 results.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-05T23:30:57Z
      DOI: 10.1016/S2213-2600(20)30041-2
      Issue No: Vol. 8, No. 4 (2020)
  • [Editorial] COVID-19: delay, mitigate, and communicate
    • Authors: The Lancet Respiratory Medicine
      First page: 321
      Abstract: On March 11, 2020, WHO declared COVID-19 a pandemic and has called for governments to take “urgent and aggressive action” to change the course of the outbreak. As of March 12, 2020, the USA has suspended all travel from 26 European countries, and Italy is the latest country to enforce widespread lockdown measures to curb the spread of the virus. Robust plans and policies to avoid the disease trajectories seen in the worst-hit countries are urgently needed. These responses must be proportionate to each country's situation and communicated in a clear and balanced way to avoid spreading fear and panic.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-16T07:40:41Z
      DOI: 10.1016/S2213-2600(20)30128-4
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Xpert MTB/RIF Ultra: what is the real impact'
    • Authors: Maryline Bonnet
      Pages: 325 - 326
      Abstract: Better access to highly sensitive tuberculosis tests to improve case detection could reduce the gap between the number of cases notified by national tuberculosis control programmes and the number of incident cases estimated by WHO. The roll-out of the more sensitive Xpert MTB/RIF Ultra (Ultra) cartridge compared with the standard Xpert MTB/RIF (Xpert) cartridge, particularly for diagnosis of patients who are smear negative for tuberculosis and HIV positive, is expected to contribute to such efforts.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-14T23:30:02Z
      DOI: 10.1016/S2213-2600(20)30050-3
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Evolving therapies for rifampicin-resistant tuberculosis:
           balancing efficacy and toxicity
    • Authors: Ebrahim Variava; Neil Martinson, Firdaus Nabeemah
      Pages: 326 - 328
      Abstract: Disease caused by Mycobacterium tuberculosis is a leading global health problem associated with severe morbidity and a high risk of death, despite widespread availability of effective treatment for drug-sensitive tuberculosis. Although drug-resistant tuberculosis had been described for many years, alarming reports over the past decade suggested neither tuberculosis transmission nor virulence was compromised by the selection of tuberculosis drug resistance.1,2 These reports, describing the prognosis of patients with extremely drug-resistant tuberculosis, galvanised global research efforts into improving treatment, which is complicated, requiring multiple drugs with a high potential for adverse events and drug–drug interactions, especially in HIV co-infected individuals on antiretroviral therapy (ART).
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-16T23:30:06Z
      DOI: 10.1016/S2213-2600(20)30038-2
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Headway made towards biosignatures for incipient tuberculosis
    • Authors: Thomas J Scriba; Simon C Mendelsohn
      Pages: 328 - 330
      Abstract: Identification of individuals with tuberculosis for antibiotic treatment is a major component of the of WHO's End TB Strategy.1 Diagnostic tests for tuberculosis rely on detection of Mycobacterium tuberculosis in sputum expectorated by a person with productive cough. The search for new sputum-independent diagnostic tests is gaining momentum, as exemplified by advances in urine-based point-of-care lipoarabinomannan lateral flow assays for use in hospitalised patients with HIV.2
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-01-17T23:30:05Z
      DOI: 10.1016/S2213-2600(19)30355-8
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Blood transcriptional signatures for tuberculosis testing
    • Authors: Simon C Mendelsohn; Stanley Kimbung Mbandi, Mark Hatherill, Thomas J Scriba
      Pages: 330 - 331
      Abstract: Case-finding strategies for tuberculosis diagnosis rely on symptom screening, which is associated with poor sensitivity,1 resultant delays in diagnosis, increased patient morbidity, and ongoing transmission. There is need for a more sensitive, non-sputum-based triage test to exclude tuberculosis at the primary care level, and for mass screening in high-burden settings.2 Several blood transcriptional diagnostic signatures have been described;3 however, these were invariably discovered and validated in carefully selected case-control cohorts, inflating diagnostic accuracy.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-13T23:30:03Z
      DOI: 10.1016/S2213-2600(20)30045-X
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Post-tuberculosis mortality and morbidity: valuing the hidden
    • Authors: Matthew Quaife; Rein M G J Houben, Brian Allwood, Ted Cohen, Anna K Coussens, Anthony D Harries, Sanne van Kampen, Florian M Marx, Sedona Sweeney, Robert S Wallis, Nicolas A Menzies
      Pages: 332 - 333
      Abstract: Case fatality rates for tuberculosis disease have fallen progressively over the past 20 years, and an estimated 54 million people have survived tuberculosis since 2000.1 More recently, there have been increasing efforts to understand the long-term implications of morbidity and mortality post tuberculosis, and a growing body of evidence describes how successful completion of treatment is unlikely to represent the end of ill health.2
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-10T23:30:05Z
      DOI: 10.1016/S2213-2600(20)30039-4
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Programmatic versus personalised approaches to managing the
           global epidemic of multidrug-resistant tuberculosis
    • Authors: Jeremiah Muhwa Chakaya; Ben Marais, Philipp du Cros, Francine Ntoumi, Sayoki Mfinanga, Nathan Kapata, Seyed Ehtesham Hasnain, Ruvandhi Nathavitharana, Alimuddin Zumla
      Pages: 334 - 335
      Abstract: The push to end tuberculosis as a global public health threat received a major boost from the first UN General Assembly high-level meeting on tuberculosis in 2018.1 To end tuberculosis by 2035, however, hurdles need to be overcome in detection, provision of care, and treatment of drug-resistant tuberculosis. In 2018, an estimated 500 000 people had rifampicin-resistant (RR) tuberculosis, of whom 78% had multidrug-resistant (MDR) tuberculosis.2 Prevalence of RR or MDR tuberculosis is higher in people who have previously been treated than in those who have never had tuberculosis treatment.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-27T23:30:02Z
      DOI: 10.1016/S2213-2600(20)30104-1
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Tuberculosis in children, adolescents, and women
    • Authors: Ben J Marais; Farhana Amanullah, Amita Gupta, Mercedes C Becerra, Kathryn Snow, Esther Ngadaya, Mukta Sharma, Anneke C Hesseling, Muhwa Chakaya, Alimuddin Zumla
      Pages: 335 - 337
      Abstract: Since tuberculosis was declared a global emergency in 1993, the introduction of the directly observed treatment short-course (DOTS) and DOTS-Plus strategies has saved millions of lives, but has had little effect on transmission. Tuberculosis remains the leading infectious disease killer on the planet. Of the 7 million new tuberculosis cases notified to WHO in 2018, 58% were men, 34% were women, and 8% were children (aged
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-27T23:30:04Z
      DOI: 10.1016/S2213-2600(20)30077-1
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Host-directed therapies and holistic care for tuberculosis
    • Authors: Alimuddin Zumla; Giuseppe Ippolito, Francine Ntoumi, Vicki Seyfert-Margolies, Tumaini J Nagu, Daniela Cirillo, Jeremiah Muhwa Chakaya, Ben Marais, Markus Maeurer
      Pages: 337 - 340
      Abstract: Multidrug-resistant (MDR) tuberculosis remains a major threat to global public health security, despite advances that include new tuberculosis drugs, treatment regimens, and rapid diagnostics. In 2018, there were an estimated half a million new cases of rifampicin-resistant tuberculosis; 78% of these cases had MDR tuberculosis.1 Current WHO treatment recommendations for MDR tuberculosis propose a combination of anti-Mycobacterium tuberculosis drugs, most of which have serious side-effects and have to be taken for 6–18 months.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-27T23:30:03Z
      DOI: 10.1016/S2213-2600(20)30078-3
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Interstitial lung diseases: a call for papers
    • Authors: Emma Grainger
      First page: 340
      Abstract: New technologies, improved diagnostics and treatments, and the introduction of multidisciplinary patient care have resulted in many advances in the treatment and management of patients with interstitial lung diseases (ILDs) and lung and airway fibrosis. To highlight some of the latest research, we will be publishing a special themed issue on ILDs to coincide with the 21st international colloquium on lung and airway fibrosis (ICLAF) on Oct 3–7, 2020, in Reykjavik, Iceland. We are therefore calling for high-quality submissions of research articles in the area of ILDs; we particularly welcome clinical trials.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-04
      DOI: 10.1016/S2213-2600(20)30131-4
      Issue No: Vol. 8, No. 4 (2020)
  • [News] Gag clause prevents discussion of assisted dying in Victoria,
    • Authors: Tony Kirby
      Pages: 341 - 342
      Abstract: On June 19, 2019, euthanasia legislation in Victoria, Australia, came into effect. The Voluntary Assisted Dying Act 2017 (Vic) allows individuals whose life expectancy is 6 months or less to seek medical assistance to end their life. Patients with certain progressive neurodegenerative conditions, such as multiple sclerosis or motor neuron disease, can apply within 1 year of their expected death. People with conditions that might hinder their decision-making capacity, such as advanced Alzheimer's disease, are excluded, as are people who have a mental illness or disability, without a terminal illness.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-02T23:30:05Z
      DOI: 10.1016/S2213-2600(20)30108-9
      Issue No: Vol. 8, No. 4 (2020)
  • [Spotlight] The role of policy in the EVALI outbreak: solution or
    • Authors: Danielle M Smith; Maciej L Goniewicz
      Pages: 343 - 344
      Abstract: The introduction of vaping as a mode of nicotine delivery has created numerous challenges in identifying the conditions under which these devices might create public health benefits or harms. Increasing use of e-cigarettes and similar vaping products to administer cannabinoids via inhalation has created important concerns among respiratory clinicians and public health advocates.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-07T23:30:07Z
      DOI: 10.1016/S2213-2600(20)30065-5
      Issue No: Vol. 8, No. 4 (2020)
  • [Spotlight] Where next for inhaled corticosteroids in childhood
    • Authors: Ian P Sinha; Susanna R Dodd, Christopher Grime, Daniel B Hawcutt, Ricardo M Fernandes, Matthew R Roberts, Justus M Simba, Paula R Williamson
      First page: 345
      Abstract: The global burden of asthma for children is immense. The Global Initiative for Asthma (GINA) strategy, used worldwide, is advocating a radical shift in how asthma is managed. In a new symptom-driven approach, GINA recommend that inhaled corticosteroids (ICS) are used only when someone with asthma feels like they need a bronchodilator, rather than as regular preventer therapy. For adolescents and adults, the new recommendation is to use, as rescue therapy, inhalers combining ICS with fast-acting, long-acting β agonist (LABA), such as formoterol.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-01-20T23:30:05Z
      DOI: 10.1016/S2213-2600(20)30013-8
      Issue No: Vol. 8, No. 4 (2020)
  • [Spotlight] Patient support is vital to treatment adherence
    • Authors: Kyi Pyar Soe
      First page: 346
      Abstract: In May 2018, Khin Mar Aye, a 40-year-old woman, attended a health education session in the Ye-U township of the Sagaing region of Myanmar when a community volunteer from The Union tuberculosis project recognised her symptoms of cough, fever, weight loss, and reduced appetite as tuberculosis. She was immediately referred to the nearest mobile clinic, run by the tuberculosis team of the Ye-U township, where she underwent sputum testing and chest x-ray screening. When the sputum smear result was positive, Gene-Xpert testing was done, and she was diagnosed with multidrug-resistant tuberculosis.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-11T23:30:13Z
      DOI: 10.1016/S2213-2600(20)30069-2
      Issue No: Vol. 8, No. 4 (2020)
  • [Spotlight] Speaking from the head and the heart
    • Authors: Jules Morgan
      Pages: 347 - 348
      Abstract: Nandita Venkatesan is one of those people who have turned personal trauma into greater good. Self-aware, driven, and highly intelligent, she has been a lifeline for many people silently suffering with tuberculosis. Drawing from her own experience, she is well placed to fight for a better global response to treat and eradicate tuberculosis. She is talking to world leaders, policy makers, health-care professionals, and the media, but also to the wider society, communities, and individuals. “Everyone needs to know about this”, she says.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-04
      DOI: 10.1016/S2213-2600(20)30129-6
      Issue No: Vol. 8, No. 4 (2020)
  • [Articles] Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of
           tuberculosis in an HIV-endemic setting with a high burden of previous
           tuberculosis: a two-cohort diagnostic accuracy study
    • Authors: Hridesh Mishra; Byron W P Reeve, Zaida Palmer, Judy Caldwell, Tania Dolby, Charissa C Naidoo, Jennifer G Jackson, Samuel G Schumacher, Claudia M Denkinger, Andreas H Diacon, Paul D van Helden, Florian M Marx, Robin M Warren, Grant Theron
      Pages: 368 - 382
      Abstract: In a setting with a high burden of previous tuberculosis, Ultra generated more non-actionable results and had diminished specificity compared with Xpert. In patients with recent previous tuberculosis, a quarter of Ultra-positive samples were indeterminate for rifampicin resistance and culture negative, suggesting that additional drug-resistance testing will probably be unsuccessful. Our data have implications for the handling of Ultra-positive results in patients with previous tuberculosis in high burden settings.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-14T23:30:05Z
      DOI: 10.1016/S2213-2600(19)30370-4
      Issue No: Vol. 8, No. 4 (2020)
  • [Articles] Drug-associated adverse events in the treatment of
           multidrug-resistant tuberculosis: an individual patient data meta-analysis
    • Authors: Zhiyi Lan; Nafees Ahmad, Parvaneh Baghaei, Linda Barkane, Andrea Benedetti, Sarah K Brode, James C M Brust, Jonathon R Campbell, Vicky Wai Lai Chang, Dennis Falzon, Lorenzo Guglielmetti, Petros Isaakidis, Russell R Kempker, Maia Kipiani, Liga Kuksa, Christoph Lange, Rafael Laniado-Laborín, Payam Nahid, Denise Rodrigues, Rupak Singla, Zarir F Udwadia, Dick Menzies, The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017
      Pages: 383 - 394
      Abstract: Fluoroquinolones, clofazimine, and bedaquiline had the lowest incidence of adverse events leading to permanent drug discontinuation, whereas second-line injectable drugs, aminosalicylic acid, and linezolid had the highest incidence. These results suggest that close monitoring of adverse events is important for patients being treated for multidrug-resistant tuberculosis. Our results also underscore the urgent need for safer and better-tolerated drugs to reduce morbidity from treatment itself for patients with multidrug-resistant tuberculosis.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-16T23:30:03Z
      DOI: 10.1016/S2213-2600(20)30047-3
      Issue No: Vol. 8, No. 4 (2020)
  • [Articles] Concise whole blood transcriptional signatures for incipient
           tuberculosis: a systematic review and patient-level pooled meta-analysis
    • Authors: Rishi K Gupta; Carolin T Turner, Cristina Venturini, Hanif Esmail, Molebogeng X Rangaka, Andrew Copas, Marc Lipman, Ibrahim Abubakar, Mahdad Noursadeghi
      Pages: 395 - 406
      Abstract: Blood transcriptional biomarkers reflect short-term risk of tuberculosis and only exceed WHO benchmarks if applied to 3–6-month intervals. Serial testing among carefully selected target groups might be required for optimal implementation of these biomarkers.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-01-17T23:30:05Z
      DOI: 10.1016/S2213-2600(19)30282-6
      Issue No: Vol. 8, No. 4 (2020)
  • [Articles] Blood transcriptional biomarkers for active pulmonary
           tuberculosis in a high-burden setting: a prospective, observational,
           diagnostic accuracy study
    • Authors: Carolin T Turner; Rishi K Gupta, Evdokia Tsaliki, Jennifer K Roe, Prasenjit Mondal, Georgina R Nyawo, Zaida Palmer, Robert F Miller, Byron WP Reeve, Grant Theron, Mahdad Noursadeghi
      Pages: 407 - 419
      Abstract: Selected blood transcriptional signatures met the minimum WHO benchmarks for a tuberculosis triage test but not for a confirmatory test. Further development of the signatures is warranted to investigate their possible effects on clinical and health economic outcomes as part of a triage strategy, or when used as add-on confirmatory test in conjunction with the highly sensitive Ultra test for Mycobacterium tuberculosis DNA.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-03-13T23:30:06Z
      DOI: 10.1016/S2213-2600(19)30469-2
      Issue No: Vol. 8, No. 4 (2020)
  • [Case Report] Pathological findings of COVID-19 associated with acute
           respiratory distress syndrome
    • Authors: Zhe Xu; Lei Shi, Yijin Wang, Jiyuan Zhang, Lei Huang, Chao Zhang, Shuhong Liu, Peng Zhao, Hongxia Liu, Li Zhu, Yanhong Tai, Changqing Bai, Tingting Gao, Jinwen Song, Peng Xia, Jinghui Dong, Jingmin Zhao, Fu-Sheng Wang
      Pages: 420 - 422
      Abstract: Since late December, 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV)1,2 was reported in Wuhan, China,2 which has subsequently affected 26 countries worldwide. In general, COVID-19 is an acute resolved disease but it can also be deadly, with a 2% case fatality rate. Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure.2,3 As of Feb 15, about 66 580 cases have been confirmed and over 1524 deaths. However, no pathology has been reported due to barely accessible autopsy or biopsy.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2020-02-18T12:00:49Z
      DOI: 10.1016/S2213-2600(20)30076-X
      Issue No: Vol. 8, No. 4 (2020)
  • [Comment] Active management of mild obstructive sleep apnoea: the evidence
    • Authors: Walter T McNicholas
      Pages: 322 - 323
      Abstract: Obstructive sleep apnoea is highly prevalent and reports indicate a prevalence for mild obstructive sleep apnoea of up to 35% in the general population.1 However, a lower prevalence of about 5% is reported in the general population for the clinical syndrome when sleep disordered breathing, as determined by the apnoea-hypopnoea index (AHI), is combined with relevant daytime manifestations such as excessive sleepiness.1,2 Because many patients with obstructive sleep apnoea, even in the mild category, report debilitating symptoms of sleepiness and other measures of impaired quality of life, the active management of such patients is an important clinical consideration.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2019-12-02T23:30:05Z
      DOI: 10.1016/S2213-2600(19)30447-3
      Issue No: Vol. 8, No. 4 (2019)
  • [Comment] Treatment for obstructive sleep apnoea and cardiovascular
           diseases: are we aiming at the wrong target'
    • Authors: Raphael Heinzer; Danny Eckert
      Pages: 323 - 325
      Abstract: Despite a robust design and good statistical power, the ISAACC study1 (Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome. Effect of intervention with CPAP), similar to the SAVE study (Sleep Apnea cardioVascular Endpoints),2 did not show a positive effect of obstructive sleep apnoea (OSA) treatment with continuous positive airway pressure (CPAP) as a secondary prevention for cardiovascular events. The modest but clinically similar use of CPAP (
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2019-12-12T23:30:02Z
      DOI: 10.1016/S2213-2600(19)30351-0
      Issue No: Vol. 8, No. 4 (2019)
  • [Spotlight] Unmasked: we all breathe
    • Authors: Talha Khan Burki
      First page: 348
      Abstract: Aaron Motsoaledi went to a primary school that overlooked a tuberculosis ward. “We would view these people as different people from ourselves”, recalls Motsoaledi, partway through Unmasked: We All Breathe. At the time of filming, he was South Africa's Minister of Health. “Generally, tuberculosis is a socioeconomic disease of the poor and so it is regarded as a lowly disease”, explains Motsoaledi. “I suspect that is where the stigma came from.”
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2019-12-20T16:52:10Z
      DOI: 10.1016/S2213-2600(19)30477-1
      Issue No: Vol. 8, No. 4 (2019)
  • [Articles] Continuous positive airway pressure versus standard care for
           the treatment of people with mild obstructive sleep apnoea (MERGE): a
           multicentre, randomised controlled trial
    • Authors: Alison J Wimms; Julia L Kelly, Christopher D Turnbull, Alison McMillan, Sonya E Craig, John F O'Reilly, Annabel H Nickol, Emma L Hedley, Meredith D Decker, Leslee A Willes, Peter M A Calverley, Adam V Benjafield, John R Stradling, Mary J Morrell, MERGE trial investigators
      Pages: 349 - 358
      Abstract: 3 months of treatment with continuous positive airway pressure improved the quality of life in patients with mild obstructive sleep apnoea. These results highlight the need for health-care professionals and providers to consider treatment for patients with mild obstructive sleep apnoea.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2019-12-02T23:30:05Z
      DOI: 10.1016/S2213-2600(19)30402-3
      Issue No: Vol. 8, No. 4 (2019)
  • [Articles] Effect of obstructive sleep apnoea and its treatment with
           continuous positive airway pressure on the prevalence of cardiovascular
           events in patients with acute coronary syndrome (ISAACC study): a
           randomised controlled trial
    • Authors: Manuel Sánchez-de-la-Torre; Alicia Sánchez-de-la-Torre, Sandra Bertran, Jorge Abad, Joaquín Duran-Cantolla, Valentín Cabriada, Olga Mediano, María José Masdeu, Mari Luz Alonso, Juan Fernando Masa, Antonia Barceló, Mónica de la Peña, Mercè Mayos, Ramón Coloma, Josep M Montserrat, Eusebi Chiner, Salvador Perelló, Gemma Rubinós, Olga Mínguez, Lydia Pascual, Anunciación Cortijo, Dolores Martínez, Albina Aldomà, Mireia Dalmases, R Doug McEvoy, Ferran Barbé, Spanish Sleep Network
      Pages: 359 - 367
      Abstract: Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence.
      Citation: The Lancet Respiratory Medicine 8, 4 (2020)
      PubDate: 2019-12-12T23:30:02Z
      DOI: 10.1016/S2213-2600(19)30271-1
      Issue No: Vol. 8, No. 4 (2019)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-